COMPAZINE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Apr 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 41m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMPAZINE (prochlorperazine) is a first-generation antipsychotic and antiemetic small molecule approved in 1957 by GSK. The drug is administered via injection and is used primarily for nausea, vomiting, and psychiatric indications. Its mechanism involves dopamine antagonism in the chemoreceptor trigger zone and central nervous system.
LOE Approaching
As an aging asset approaching loss of exclusivity with moderate competitive pressure (30/100), teams are typically lean and focused on defensive tactics rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on COMPAZINE offers limited career growth due to its LOE-approaching lifecycle and minimal linked job openings (0 recorded). Career value lies in managing legacy products, defending market share, and gaining market access expertise rather than innovation or expansion.
Brand Manager (defensive)Medical Science Liaison
Worked on COMPAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.